DHL Group invests €2bn in healthcare logistics push
DHL Group has unveiled a major expansion of its dedicated Life Sciences & Healthcare (LSH) airfreight cold chain network, strengthening its position in the fast-growing pharmaceutical logistics market.
The initiative forms a core element of the company’s €2 billion strategic investment in DHL Health Logistics and is designed to enhance the movement of temperature-sensitive medicines, vaccines, pharmaceutical products and advanced cell and gene therapies worldwide.
According to DHL, the expanded network provides full end-to-end visibility for sensitive healthcare shipments while connecting key global markets through more than 30 GDP-compliant aviation hubs and gateways.
Oscar de Bok, chief executive of DHL Global Forwarding, said: “Life sciences and healthcare companies expect cold chain solutions that are reliable, compliant, and transparent from end to end – and those expectations are rising fast. At the same time, they’re looking for ways to simplify supply chains and reduce costs.
“Our expanded network brings together DHL Aviation‘s global air connectivity, our GDP-compliant station network, and our major investments in modern, temperature-controlled facilities. The result is a more resilient, more efficient logistics backbone for customers who depend on flawless quality to deliver critical therapies to patients.”
A central pillar of the rollout is a dedicated Boeing 777F operating between Brussels (BRU) and Cincinnati (CVG), directly linking two of the world’s most important healthcare markets.
The corridor connects the US Midwest – home to leading pharma manufacturers – with one of Europe’s most advanced life sciences clusters.
At the Brussels end, shipments are supported by 45,000 sqm of pharma-only zones at BRUcargo, providing clinical-grade temperature control throughout the handling process.
DHL says the dedicated routing reduces reliance on third-party carriers and commercial belly capacity, improving product integrity while strengthening resilience against geopolitical disruption, capacity shortages and regulatory complexity.
The company adds that its investment in temperature-controlled infrastructure also reduces the need for heavy packaging and refrigerated containers, helping customers lower costs while minimising temperature excursions.
With patient safety positioned at the centre of the service, DHL said the expanded network underlines its long-term commitment to strengthening global health logistics and meeting rising demand for fast, reliable, temperature-controlled pharmaceutical transport.
READ MORE NEWS: DHL Aviation expands West African reach with two more freighters
The post DHL Group invests €2bn in healthcare logistics push appeared first on Aviation Business News.